| Literature DB >> 33941126 |
Randi Dalene Bjerke1, Ida Laake2, Berit Feiring3, Geir Aamodt1, Lill Trogstad3.
Abstract
BACKGROUND: Since the human papillomavirus (HPV) vaccine was introduced in Norway in 2009, the vaccine uptake has increased. Whether this increase is similar regardless of the girls' country background is unknown. We examined changes in HPV vaccine uptake from 2009 to 2014 and studied the impact of parental education and income on HPV vaccine uptake according to country background.Entities:
Keywords: Childhood immunisation programme; HPV vaccine; Human papillomavirus; Immigrant background; Income; Parental education; Socioeconomic factors; Time trends
Year: 2021 PMID: 33941126 PMCID: PMC8091748 DOI: 10.1186/s12889-021-10877-8
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Flow chart of study population
Characteristics of the study population. Girls offered HPV vaccine during 2009–2014 (n = 177,387)
| n (%) | |
|---|---|
| Initiated | 146,403 (82.5) |
| Did not initiate | 30,984 (17.5) |
| Norway | 158,738 (89.5) |
| Western Europe | 2072 (1.2) |
| Central- and Eastern Europe | 3887 (2.2) |
| Middle East and North Africa | 3729 (2.1) |
| South-Asia | 3355 (1.9) |
| East−/South-East Asia | 2236 (1.3) |
| Sub-Saharan Africa | 2775 (1.6) |
| America and Oceania | 595 (0.3) |
| 1997 (2009) | 30,209 (17.0) |
| 1998 (2010) | 29,719 (16.8) |
| 1999 (2011) | 30,100 (17.0) |
| 2000 (2012) | 30,098 (17.0) |
| 2001 (2013) | 28,932 (16.3) |
| 2002 (2014) | 28,329 (16.0) |
| Primary school/compulsory level (≤ 10) | 32,865 (18.5) |
| Upper secondary level (11–14) | 66,711 (37.6) |
| Higher education, undergraduate level (14–17) | 63,003 (35.5) |
| Higher education, graduate level (≥ 18) | 14,808 (8.4) |
| 1 (≤ 575,319) | 34,736 (19.6) |
| 2 (575,320–811,300) | 35,412 (20.0) |
| 3 (811,301–988,227) | 35,704 (20.1) |
| 4 (988,228–1,251,798) | 35,778 (20.2) |
| 5 (≥ 1,251,799) | 35,757 (20.2) |
| 0 | 8203 (4.6) |
| 1 | 66,237 (37.3) |
| 2 | 62,468 (35.2) |
| 3 | 24,561 (13.9) |
| ≥ 4 | 15,918 (9.0) |
| ≤ 25 | 38,939 (22.0) |
| 26–30 | 64,254 (36.2) |
| 31–35 | 51,947 (29.3) |
| > 35 | 22,247 (12.5) |
| Oslo | 15,889 (9.0) |
| Eastern-Norway | 45,259 (25.5) |
| Southern-Norway | 34,892 (20.1) |
| Western-Norway | 39,283 (22.2) |
| Mid-Norway | 24,948 (14.1) |
| Northern-Norway | 17,116 (9.7) |
HPV Human papillomavirus
aList of countries in each category is provided in the Supplementary table
bEach programme year, the vaccine was offered to only one birth cohort
HPV vaccination uptake among girls offered HPV vaccine during 2009–2014 (n = 177,387)
| HPV vaccine uptake | Univariable model | Multivariable model | |||
|---|---|---|---|---|---|
| RD (95% CI) | RD (95% CI) | ||||
| Norway | 131,185 (82.6) | 0 (Ref) | 0 (Ref) | ||
| Western Europe | 1544 (74.5) | −8.1 (−10.1 to −6.2) | < 0.001 | −7.9 (−9.7 to −6.1) | < 0.001 |
| Central- and Eastern Europe | 3098 (79.7) | −2.9 (−4.2 to − 1.7) | < 0.001 | −3.3 (−4.6 to − 2.1) | < 0.001 |
| Middle East and North Africa | 3079 (82.6) | −0.1 (− 1.3 to 1.2) | 0.91 | 0.8 (− 0.4 to 2.0) | 0.20 |
| South-Asia | 2925 (87.2) | 4.5 (3.4 to 5.7) | < 0.001 | 4.9 (3.8 to 5.9) | < 0.001 |
| East−/South-East Asia | 1987 (88.9) | 6.2 (4.9 to 7.5) | < 0.001 | 5.4 (4.3 to 6.6) | < 0.001 |
| Sub-Saharan Africa | 2130 (76.8) | −5.9 (−7.4 to −4.3) | < 0.001 | −3.4 (− 5.0 to − 1.8) | < 0.001 |
| America and Oceania | 455 (76.5) | −6.2 (−9.5 to − 2.7) | < 0.001 | − 5.5 (− 8.8 to − 2.2) | 0.001 |
| 1997 (2009) | 21,896 (72.5) | 0 (Ref) | 0 (Ref) | ||
| 1998 (2010) | 24,086 (81.1) | 8.5 (7.9 to 9.2) | < 0.001 | 8.6 (8.0 to 9.3) | < 0.001 |
| 1999 (2011) | 25,136 (83.5) | 11.0 (10.4 to 11.7) | < 0.001 | 11.2 (10.5 to 11.8) | < 0.001 |
| 2000 (2012) | 25,463 (84.6) | 12.1 (11.5 to 12.8) | < 0.001 | 12.4 (11.7 to 13.0) | < 0.001 |
| 2001 (2013) | 25,104 (86.8) | 14.3 (13.7 to 14.9) | < 0.001 | 14.4 (13.8 to 15.1) | < 0.001 |
| 2002 (2014) | 24,718 (87.3) | 14.8 (14.1 to 15.4) | < 0.001 | 15.1 (14.5 to 15.7) | < 0.001 |
| Primary school/compulsory level | 26,946 (82.0) | 0 (Ref) | 0 (Ref) | ||
| Upper secondary level | 55,157 (82.7) | 0.7 (0.2 to 1.2) | 0.007 | −0.1 (−0.6 to 0.4) | 0.64 |
| Higher education, undergraduate level | 52,132 (82.8) | 0.8 (0.2 to 1.3) | 0.004 | −0.8 (−1.4 to − 0.3) | 0.001 |
| Higher education, graduate level | 12,168 (82.2) | 0.2 (−0.6 to 0.9) | 0.63 | −1.6 (−2.3 to − 0.8) | < 0.001 |
| 1 (≤ 575,319) | 27,687 (79.7) | 0 (Ref) | 0 (Ref) | ||
| 2 (575320–811,300) | 28,874 (81.5) | 1.8 (1.2 to 2.4) | < 0.001 | 1.4 (0.9 to 2.0) | < 0.001 |
| 3 (811301–988,227) | 29,888 (83.7) | 4.0 (3.4 to 4.5) | < 0.001 | 3.7 (3.1 to 4.2) | < 0.001 |
| 4 (988228–1,251,798) | 29,972 (83.8) | 4.1 (3.5 to 4.6) | < 0.001 | 4.2 (3.7 to 4.8) | < 0.001 |
| 5 (≥ 1,251,799) | 29,982 (83.9) | 4.1 (3.5 to 4.7) | < 0.001 | 4.9 (4.3 to 5.5) | < 0.001 |
| 0 | 6558 (80.0) | 0 (Ref) | 0 (Ref) | ||
| 1 | 55,421 (83.7) | 3.7 (2.8 to 4.6) | < 0.001 | 2.9 (2.0 to 3.8) | < 0.001 |
| 2 | 52,142 (83.5) | 3.5 (2.6 to 4.4) | < 0.001 | 2.5 (1.7 to 3.4) | < 0.001 |
| 3 | 19,825 (80.7) | 0.8 (−0.2 to 1.8) | 0.13 | 0.4 (− 0.5 to 1.4) | 0.37 |
| ≥ 4 | 12,457 (78.3) | −1.7 (−2.8 to − 0.6) | 0.002 | −1.2 (− 2.3 to − 0.2) | 0.02 |
| ≤ 25 | 32,515 (83.5) | 0 (Ref) | 0 (Ref) | ||
| 26–30 | 53,690 (83.6) | 0.1 (−0.4 to 0.5) | 0.81 | −0.8 (−1.3 to − 0.4) | < 0.001 |
| 31–35 | 42,760 (82.3) | − 1.2 (− 1.7 to − 0.7) | < 0.001 | −2.3 (− 2.8 to − 1.8) | < 0.001 |
| > 35 | 17,438 (78.4) | −5.1 (−5.8 to −4.5) | < 0.001 | −5.4 (−6.1 to −4.8) | < 0.001 |
| Oslo | 12,968 (81.6) | 0 (Ref) | 0 (Ref) | ||
| Eastern-Norway | 37,721 (83.3) | 1.7 (1.0 to 2.4) | < 0.001 | 1.1 (0.4 to 1.8) | 0.001 |
| Southern-Norway | 28,671 (82.2) | 0.6 (− 0.2 to 1.3) | 0.13 | 0.1 (− 0.6 to 0.9) | 0.69 |
| Western-Norway | 32,551 (82.9) | 1.2 (0.5 to 2.0) | 0.001 | 0.4 (−0.3 to 1.1) | 0.28 |
| Mid-Norway | 20,321 (81.5) | −0.2 (− 0.9 to 0.6) | 0.68 | − 0.6 (− 1.3 to 0.2 | 0.15 |
| Northern-Norway | 14,171 (82.8) | 1.2 (0.4 to 2.0) | 0.005 | 0.7 (−0.1 to 1.5) | 0.09 |
HPV human papillomavirus, RD risk difference, CI confidence interval
a Receipt of at least one dose of HPV vaccine
b Risk differences are estimated with linear binomial regression
c The model included country background, year of birth, parental education level, household income, number of siblings, maternal age at time of
daughter’s birth, and region of residence
d List of countries in each category is provided in the Supplementary table
e Each programme year, the vaccine was offered to only one birth cohort
Fig. 2Uptake of at least one dose of HPV vaccine according to country of origin
Increase in HPV vaccine uptake per year (2009–2014) according to country background
| HPV vaccine uptake | Multivariable model | |||
|---|---|---|---|---|
| 2009 | 2014 | |||
| RD (95% CI) | ||||
| Norway | 19,706 (72.1) | 22,023 (87.9) | 2.7 (2.6 to 2.8) | < 0.001 |
| Europe, America, and Oceania | 684 (73.7) | 936 (77.8) | 1.0 (0.4 to 1.6) | 0.001 |
| Middle East and Africa | 755 (75.2) | 954 (81.8) | 1.3 (0.7 to 1.8) | < 0.001 |
| Asia | 751 (80.7) | 805 (90.2) | 1.6 (1.2 to 2.1) | < 0.001 |
HPV Human papillomavirus, RD Risk difference, CI Confidence interval
aReceipt of at least one dose of HPV vaccine
bRisk differences are estimated with linear binomial regression. The model included country background, year of birth (corresponding to programme year), parental education level, household income, number of siblings, maternal age at time of daughter’s birth, region of residence, and interaction terms between country background and year of birth. RDs correspond to the change in HPV vaccine uptake per year
cList of countries in each category is provided in the Supplementary table
Impact of parental education on HPV vaccine uptake according to country background
| Higher education | HPV vaccine uptake | Multivariable model | |||
|---|---|---|---|---|---|
| Lower education | Higher education | ||||
| RD (95% CI) | |||||
| Norway | 73,023 (46.0) | 70,561 (82.3) | 60,624 (83.0) | − 0.6 (−1.0 to − 0.2) | 0.005 |
| Europe, America, and Oceania | 2576 (39.3) | 3199 (80.4) | 1898 (73.7) | −7.8 (− 9.9 to − 5.6) | < 0.001 |
| Middle East and Africa | 1121 (17.2) | 4328 (80.4) | 881 (78.6) | −2.7 (−5.3 to − 0.02) | 0.048 |
| Asia | 1091 (19.5) | 4015 (89.2) | 897 (82.2) | −8.1 (−10.5 to −5.6) | < 0.001 |
HPV Human papillomavirus, RD Risk difference, CI Confidence interval
a Receipt of at least one dose of HPV vaccine
b Risk differences are estimated with linear binomial regression. The model included country background, year of birth, parental education level, household income, number of siblings, maternal age at time of daughter’s birth, region of residence, and interaction terms between country background and parental education level. RDs correspond to the difference in HPV vaccine uptake between girls with higher parental education and girls with lower parental education
c List of countries in each category is provided in the Supplementary table
Impact of household income on HPV vaccine uptake according to country background
| Household income, | Multivariable model | ||
|---|---|---|---|
| median (NOK) | RD (95% CI) | ||
| Norway | 930,136 | 0.2 (0.1 to 0.4) | < 0.001 |
| Europe, America, and Oceania | 685,123 | − 0.2 (− 0.6 to 0.3) | 0.44 |
| Middle East and Africa | 534,160 | 2.1 (1.2 to 3.0) | < 0.001 |
| Asia | 698,839 | −0.4 (− 1.0 to 0.2) | 0.19 |
HPV Human papillomavirus, RD Risk difference, CI Confidence interval
a Risk differences are estimated with linear binomial regression. The model included country background, year of birth, parental education level, household income, number of siblings, maternal age at time of daughter’s birth, region of residence, and interaction terms between country background and household income. RDs correspond to the difference in HPV vaccine uptake between households with a 200,000 NOK difference in household income
b List of countries in each category is provided in the Supplementary table